Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 9368 | onartuzumab |
| Synonyms |
| MetMAb | OA-5D5 | OA5D5 | PRO 143966 |
| Comments |
| Onartuzumab is an investigational, humanized monoclonal antibody targeting the MET receptor tyrosine kinase, a proto-oncogene which acts as a hepatocyte growth factor receptor. The protein is a monovalent (single-armed) construct, as opposed to bi-valent intact antibody structures. Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide analysis reveals identical match with sequences deposited with patent US7615529 [4], which relate to the monoclonal isolated from hybridoma 5D5.11.6 therein. |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 368 |
| Other databases | |
| GtoPdb PubChem SID | 310264746 |
| Search PubMed clinical trials | onartuzumab |
| Search PubMed titles | onartuzumab |
| Search PubMed titles/abstracts | onartuzumab |
